On the morning of August 17, CXO company Kingsley Biotech's stock price surged 6.67%. The night before, the semi-annual report released by Kingsley showed that in the first half of 2026, according to a comparable scale, the company achieved revenue of about 404 million US dollars, an increase of 27.3% year on year; adjusted net profit was about 62.5 million US dollars, an increase of 203.3% year on year. This net profit reached a record high for the same period in history.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.